-       Report 
   - November 2025
    -  458 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1079EUR$1,200USD£946GBP 
      €1348EUR$1,500USD£1,182GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2426EUR$2,699USD£2,128GBP 
                -       Report 
   - July 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                  -       Drug Pipelines 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1079EUR$1,200USD£946GBP 
      €1348EUR$1,500USD£1,182GBP 
                   -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €899EUR$1,000USD£788GBP 
      €1124EUR$1,250USD£985GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2426EUR$2,699USD£2,128GBP 
                -       Drug Pipelines 
   - June 2025
    -  200 Pages 
    Global
   
   From       €2507EUR$2,789USD£2,198GBP 
                -       Clinical Trials 
   - March 2025
    -  398 Pages 
    Global
   
   From       €3101EUR$3,450USD£2,720GBP 
                -       Report 
   - November 2025
    -  159 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1438EUR$1,600USD£1,261GBP 
      €1798EUR$2,000USD£1,577GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - May 2024
    -  131 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                -       Clinical Trials 
   - May 2024
    -  63 Pages 
    Global
   
   From       €2247EUR$2,500USD£1,971GBP 
                -       Report 
   - September 2023
    -  369 Pages 
    Global
   
   From       €2247EUR$2,500USD£1,971GBP 
                -       Report 
   - December 2022
    -  69 Pages 
    Global
   
   From       €1798EUR$2,000USD£1,577GBP 
             
         Meningitis is an inflammation of the membranes that cover the brain and spinal cord. Meningitis drugs are used to treat the infection and reduce the risk of complications. These drugs are typically antibiotics, antivirals, or antifungals, and may be administered orally, intravenously, or intramuscularly. Commonly used antibiotics include cefotaxime, ceftriaxone, and vancomycin. Antivirals such as acyclovir and valacyclovir are used to treat viral meningitis, while antifungals such as amphotericin B    and fluconazole are used to treat fungal meningitis.
Meningitis drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological conditions. These drugs are used to treat conditions such as epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
Some companies in the Meningitis Drug market include Pfizer, Merck, GlaxoSmithKline, Novartis, and Sanofi. Show Less   Read more